Clinical Trial Update: NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial [Phase 2]

View source ↗

Summary

A Phase II clinical trial (NANT 2021-01) evaluating sequential Temozolomide, Irinotecan, NK cell therapy, and a GD2 monoclonal antibody for neuroblastoma; recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Irinotecan (Irinotecan)
• Natural Killer cell therapy (natural killer cell therapy)
• Temozolomide (Temozolomide)
• dinutuximab (dinutuximab)

Snippet

Sponsor: New Approaches to Neuroblastoma Therapy Consortium | Conditions: Neuroblastoma | Phase 2 | Status: RECRUITING